Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology, focused on sexual health, today announces that it has entered into a ground breaking licensing agreement with Haleon plc ("Haleon"), a world leading consumer healthcare Company for the rights to exclusively commercialise the Company's innovative topical, gel-based Erectile Dysfunction ("ED") treatment MED3000, in the USA.
Haleon planning 'hundreds of job cuts in the UK and worldwide'.
"We've announced internally a number of changes across our global business this week, as we continue to evolve Haleon into a more agile organisation,"Haleon spokesperson said in an email to Reuters.
Those laid off are expected to leave in September.
Price of $800 million mentioned, so that could be another slice of debt paid off.
Time will tell
Haleon is notifying interested businesses it is considering Nicotinell brand of nicotine gum, patches and lozenges to
be sold.
SP may go north.
My apologies.
I refer to Aquafresh toothpaste - it is market leader.
Sensodyne toothpaste is more premium brand / expensive compared to Aquafresh.
Both are Haleon products and well stocked in Supermarkets / Pharmacy's ,etc
Had these shares for a while thanks to a big investment in GSK. In our house we've stopped buying any of the top "brands" unless they are the cheapest. As budgets tighten with the calamity of rising mortgages and food inflation I expect many others will start to cut back. Yet Haleon has been quite resilient so far. I find it hard to think of this stock as a defensive play so I'm thinking of selling out, perhaps at 340p+. Am I missing something?
Inflation is striking Sensodyne toothpaste.
Not selling 125ml tubes - now 100ml sizes.
However, Colgate is now 75ml tubes but bigger packaging.
Surely, consumers can see through Colgate deceit.
And suddenly the huge stock overhang doesn’t seem quite as scary.
If they can do it once,it hopefully will be easy to repeat.
And it will be nice to have some big shareholders you want to be invested here.
And no sales from either for 60 days.( about 2nd week in July)
Just before half year results 2nd August
Further to "meoryou" post a bit more information on the sale to institutional investors.
Reuters "British drugmaker GSK (GSK.L) on Friday sold 240 million shares in its consumer healthcare business Haleon (HLN.L) at 335 pence per share, raising about 804 million pounds ($1 billion)... The sale price represents a 2.3% discount to Haleon's closing price of 342.85 pence on Thursday and lowers the stake of GSK, the second-largest shareholder, to 10.3%... GSK and Pfizer have agreed to not sell any further Haleon shares for 60 days."
In another article on Fierce Pharma websit "Just last week, Pfizer, which has a 32% stake in Haleon, told the Financial Times that it would begin a “slow and methodical” sale of its holdings.“We love the Haleon business but it's not strategic,” Pfizer’s chief financial officer Dave Denton . Pfizer’s Haleon stake is worth just over 10 billion pounds ($12.5 billion)."
May 12 (Reuters) - British drugmaker GSK on Friday sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1 billion), the company said.
Further information to be found in HLN news on this site
I knew it wasn’t totally the answer and obviously HLN could not borrow that kind of money to buy back.
However the £15 bill overhang would not be worth as much if they did try to start dumping them.
So an offer for some might be seen as a good compromise by both sides ,instead of this continuing to be a negative for both parties.
Or like you say someone who wants it may step in and buy up.
Probably not ULVR even though they would be buying much cheaper than their offer.
It’s sometimes not easy to exit one of these situations
It's a problem of scale , the overhang of shares in the hands of reluctant holders is almost 5bill. worth around £15bill, the only viable medium-term solution is sale to a more willing holder who wants part (or all?) of HLN. At average volumes it would take several years to drip them into the market without driving the price down substantially . In truth when the GSK board engineered the split, they ensured that the bit where they personally remain is viable(assuming a reasonable flow of new treatments) while the rest was thrown overboard and had a concrete lifebelt thrown to it.
To add to below
If they started a div reinvestment scheme they could then get market price to slowly feed them back in after purchase.
And they obviously could be used for BOD bonus options.
I’m sure there is a good reason why it’s not a goer.
One partial solution might be for HLN to get authority to repurchase some of them.
Since they have managed to drop the debt they could likely borrow £1 billion.
Since Pfizer would likely be selling into a falling market, there could be a deal to be made.
This might be acceptable to Pfizer since it could possibly be repeated every couple of years as HLN would need a breather to get debt back on track.
Just really thinking out loud, don’t know if it’s possible or likely.
Hi Box... I was a holder of both ULVR and GSK at the time of the ULVR approach for what is now essentially HLN, and said that GSK's failure to sell was idiocy. time has, I think proved me right. HLN is in a bind, almost half of its stock is owned by Pfizer and GSK and BOTH are committed to selling .I said in a post months ago that I felt that would be a drag on HLN's SP regardless of how well sales and profits went , indeed as the SP rises so the likelihood of sales by GSK/PFE grows.
The SP here is essentially flat since launch and is IMV unlikely to rise much from here . the recent piece in the FT see
https://www.ft.com/content/ec441144-52ae-4fa2-8a04-4238db0ee504?emailId=9ddd2df7-69d5-44e6-896f-f501dd3a51d9&segmentId=69ce8bbf-afc9-7c01-fb70-6e4448aa1f37
reminds everyone that large scale potential sales will be a drag on SP performance for months, possibly years. A persistent and committed seller of a a very large block of stock cannot be good news.
Just wondering how the Pfizer share sale of Haleon will affect the share price. Could these be sold in dribs and drabs and keep the price depressed for months or is it possible that one buyer could take the lot? I would imagine that many people who have Haleon after the GSK split may take this opportunity to offload their holding now. Any thoughts?
Several posts from when last div announced below
Think it currently makes sense for minimal div while debts are high.Good to see debt drop by approx 10%
I was a little surprised to see such a small dividend on the back of such healthy looking results.
But if they are reducing the sizeable debt then it will be worth a little short term pain.....
I agree that a reduction in HLN debt would be a good move for longer term rewards, and as such I would like to see it reduced over the next few years, even at the expense of higher dividends.
Currently all about reducing the debt GSK loaded onto the company at the split
According to div max ex Div date is 14th Sept payment date is 27th Oct as for how much no idea.....But your right last divi was paltry....
Does anyone have a dividend forecast for 2023? Since the demerger I have found information about this difficult to find. The final dividend just paid seemed paltry and no indication was given in the final results about future payouts.
...for starters:
https://www.***************************/haleon-plc-10.0-potential-upside-indicated-by-barclays/4121116782
This has to be a keeper, and add on the dips. IMO. I am well in profit through that strategy.
HLN have got permission to purchase their own shares in the market and to make off market purchases of their shares from Pfizer and GSK.
it would have to be higher than the previous offer - not sure that Unilever are in a good enough shape to make an offer with shareholder approval
Longtime do you think Unilever will come back with another offer?